Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

ADTX - Aditxt, Inc.

IEX Last Trade
0.2
0.002   1.000%

Share volume: 47,696
Last Updated: Thu 26 Dec 2024 07:11:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.20
0.00
1.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
33%
Profitability 50%
Dept financing 50%
Liquidity 1%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-1.39%
1 Month
-44.10%
3 Months
-15.99%
6 Months
-86.73%
1 Year
-95.88%
2 Year
-83.68%
Key data
Stock price
$0.20
P/E Ratio 
-0.05
DAY RANGE
$0.18 - $0.20
EPS 
-$39.79
52 WEEK RANGE
$0.12 - $8.47
52 WEEK CHANGE
-$96.17
MARKET CAP 
2.313 M
YIELD 
N/A
SHARES OUTSTANDING 
3.603 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.96
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$4,191,841
AVERAGE 30 VOLUME 
$2,024,362
Company detail
CEO: Amro Albanna
Region: US
Website: aditxt.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Aditxt, Inc. develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies.

Recent news